The latest BTOS survey reveals a stark divide in AI adoption across industries and regions, raising questions about economic inequality and the future of work.
In a pivotal meeting, Anthropic's CEO discusses the groundbreaking AI model Mythos with top officials, raising questions about its potential and risks.
OpenAI's GPT-Rosalind is set to revolutionize drug discovery, promising to accelerate timelines and reduce costs while raising important ethical questions.
Anthropic's exploration into custom AI chips could redefine the tech landscape, offering a glimpse into a future where companies control their own computational destinies.
In a dramatic pivot, Putin declares a digital independence, aiming to catapult Russia into the forefront of the global tech race with homegrown AI solutions.
A groundbreaking conference at the University of Scranton aims to tackle the complex ethical dilemmas posed by AI, bringing together voices from academia, media, and even the Church.
Anthropic's $400 million acquisition of Coefficient Bio signals a seismic shift in drug discovery, merging AI with biotech to tackle humanity's toughest health challenges.